Source 1review2026MED
Toolkit/HIV bNAb-derived CARs
HIV bNAb-derived CARs
Also known as: HIV Env/bNAb-based CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
High-signal enrichment leads were found primarily in PubMed/PMC and ClinicalTrials sources, with strongest support for HIV Env/bNAb-based CARs. Explicitly supported related components/tools include HIV bNAb-derived CAR binders (VRC01, 3BNC117, 10-1074).
Usefulness & Problems
Why this is useful
This construct class uses broadly neutralizing antibody-derived binding domains as the recognition module in HIV-directed CAR-T cells. The supplied evidence explicitly ties VRC01, 3BNC117, and 10-1074 to this approach.; designing HIV-targeted CAR recognition modules; targeting HIV Env with antibody-derived CAR binders
Source:
This construct class uses broadly neutralizing antibody-derived binding domains as the recognition module in HIV-directed CAR-T cells. The supplied evidence explicitly ties VRC01, 3BNC117, and 10-1074 to this approach.
Source:
designing HIV-targeted CAR recognition modules
Source:
targeting HIV Env with antibody-derived CAR binders
Problem solved
It addresses the need for HIV-specific target recognition in antiviral CAR-T engineering.; provides antigen-recognition domains for HIV-directed CAR-T designs
Source:
It addresses the need for HIV-specific target recognition in antiviral CAR-T engineering.
Source:
provides antigen-recognition domains for HIV-directed CAR-T designs
Problem links
provides antigen-recognition domains for HIV-directed CAR-T designs
LiteratureIt addresses the need for HIV-specific target recognition in antiviral CAR-T engineering.
Source:
It addresses the need for HIV-specific target recognition in antiviral CAR-T engineering.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Target processes
selectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator
It requires a CAR design incorporating an HIV bNAb-derived binder. The payload does not provide further build or assay details.; requires an HIV bNAb-derived recognition domain such as VRC01, 3BNC117, or 10-1074
The supplied evidence does not show that this design class alone solves persistence, exhaustion, delivery, or resistance problems.; the supplied payload does not provide construct architecture or comparative performance details
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review explicitly names gp350 and LMP1 as EBV CAR target leads, and names BRG01 as a gp350-targeted autologous CAR-T product in clinical development.
The review explicitly names HBsAg-related and PreS1-related HBV CAR strategies, including 4D06 and 4D08 as HBV-directed binder leads.
The review explicitly names VRC01, 3BNC117, and 10-1074 as HIV broadly neutralizing antibody-derived CAR binder leads.
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
The review explicitly names CCR5-locus knock-in and C34-CXCR4 as HIV-protective engineering features relevant to antiviral CAR-T design.
Approval Evidence
1 source1 linked approval claimfirst-pass slug hiv-bnab-derived-cars
High-signal enrichment leads were found primarily in PubMed/PMC and ClinicalTrials sources, with strongest support for HIV Env/bNAb-based CARs. Explicitly supported related components/tools include HIV bNAb-derived CAR binders (VRC01, 3BNC117, 10-1074).
Source:
design landscape summarysupports
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
Source:
Comparisons
Source-stated alternatives
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Source-backed strengths
strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class
Source:
strongest support among HIV-related tools in the supplied evidence
Source:
multiple named binder options are explicitly associated with this design class
Compared with CAR-T
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with CAR-T cells
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with CAR-T cell therapy
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with CAR-T therapy
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with chimeric antigen receptor T cells
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with Chimeric antigen receptor T-cell therapy
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Compared with TCR-T
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: strongest support among HIV-related tools in the supplied evidence; multiple named binder options are explicitly associated with this design class.
Relative tradeoffs: the supplied payload does not provide construct architecture or comparative performance details.
Source:
The payload also points to neighboring engineered antiviral T-cell modalities such as TCR-T and to additional protective engineering features layered onto HIV CAR-T cells.
Ranked Citations
- 1.